Literature DB >> 20647023

Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue.

Md Nazir Hossen1, Kazuaki Kajimoto, Hidetaka Akita, Mamoru Hyodo, Taichi Ishitsuka, Hideyoshi Harashima.   

Abstract

Ligand-based targeted delivery is an emerging platform in nanomedicine. We report herein on a peptide modified nanocarrier for a ligand-based targeted delivery system. The liposomal surface of the carrier was first modified with a linear peptide, followed by an adipose tissue-specific circular peptide (KGGRAKD) via a polyethylene glycol (PEG) spacer. To evaluate the specificity of the carrier, we purified primary cells from the endothelium of adipose tissue. The liposomes bound only to isolated primary cultured endothelial cells derived from inguinal adipose tissue (pcEC-IWAT) and not to other endothelial cell lines, such as MBEC-4 and MFLM-4. Cellular uptake was confirmed both qualitatively and quantitatively by confocal laser scanning microscopy (CLSM) and flow cytometry. The mechanism for the intracellular uptake of tPep-PEG-LPs into pcEC-IWAT, as evidenced by three independent experiments, involves saturation of receptor binding sites by excess free peptide, the blocking of receptors by an anti-prohibitin antibody and low temperature (4°C) experiments, resulting in the inhibition of uptake of tPep-PEG-LPs into pcEC-IWAT, suggesting that receptor mediated endocytosis largely contributed to the observed cellular uptake. A co-localization study using double labeled modified liposomes (lipid membrane: NBD-DOPE and aqueous phase: rhodamine) indicated that a predominant part of tPep-PEG-LPs was found without co-localization with lysosomes and retained their intactness. The selective delivery of tPep-PEG-LPs to endothelial cells in adipose tissue represents a potential approach for the design of diverse nanocarrier-based targeted delivery systems for targeting the vasculature in adipose tissue.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20647023     DOI: 10.1016/j.jconrel.2010.07.100

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  25 in total

1.  A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.

Authors:  Kirstin F Barnhart; Dawn R Christianson; Patrick W Hanley; Wouter H P Driessen; Bruce J Bernacky; Wallace B Baze; Sijin Wen; Mei Tian; Jingfei Ma; Mikhail G Kolonin; Pradip K Saha; Kim-Anh Do; James F Hulvat; Juri G Gelovani; Lawrence Chan; Wadih Arap; Renata Pasqualini
Journal:  Sci Transl Med       Date:  2011-11-09       Impact factor: 17.956

Review 2.  Nanocarrier Hydrodynamics and Binding in Targeted Drug Delivery: Challenges in Numerical Modeling and Experimental Validation.

Authors:  Portonovo S Ayyaswamy; Vladimir Muzykantov; David M Eckmann; Ravi Radhakrishnan
Journal:  J Nanotechnol Eng Med       Date:  2013-07-11

Review 3.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

4.  Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers.

Authors:  Andres J Calderon; Tridib Bhowmick; John Leferovich; Bharat Burman; Benjamin Pichette; Vladimir Muzykantov; David M Eckmann; Silvia Muro
Journal:  J Control Release       Date:  2010-11-01       Impact factor: 9.776

5.  Effect of estrogen on expression of prohibitin in white adipose tissue and liver of diet-induced obese rats.

Authors:  Minji Choi; Harmesh N Chaudhari; Young Rae Ji; Zae Young Ryoo; Sang Woo Kim; Jong Won Yun
Journal:  Mol Cell Biochem       Date:  2015-06-06       Impact factor: 3.396

6.  Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.

Authors:  N A Doudican; S J Orlow
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

7.  Therapeutic assessment of cytochrome C for the prevention of obesity through endothelial cell-targeted nanoparticulate system.

Authors:  Md Nazir Hossen; Kazuaki Kajimoto; Hidetaka Akita; Mamoru Hyodo; Taichi Ishitsuka; Hideyoshi Harashima
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

Review 8.  Dynamic factors controlling targeting nanocarriers to vascular endothelium.

Authors:  Vladimir R Muzykantov; Ravi Radhakrishnan; David M Eckmann
Journal:  Curr Drug Metab       Date:  2012-01       Impact factor: 3.731

Review 9.  The role and therapeutic potential of prohibitin in disease.

Authors:  Arianne L Theiss; Shanthi V Sitaraman
Journal:  Biochim Biophys Acta       Date:  2011-02-04

Review 10.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.